The Globe and Mail reports in its Wednesday, April 16, edition that TD Cowen analyst Tim James thinks downside earnings and 12-month target risk related to tariffs/economy for 2025 and 2026 earnings are already discounted in the share prices of Canadian cargo transportation providers. The Globe's David Leeder writes in the Eye On Equities column that Mr. James adds, "Headline risk remains elevated and likely limits short-term upside until greater certainty exists, in our view." Mr. James continues to rate Andlauer Healthcare Group "buy." Mr. James gave his share target a $2 trim to $51. Analysts on average target the shares at $48.50. Mr. James says in a note: "We forecast revenue of $162-million (flat year-over-year; cons: $167-million) and EBITDA of $39.5-million (flat year-over-year; cons: $42.2-million). Canadian ground transportation growth to offset decline in fuel surcharges and U.S. TL revenue (volume and pricing headwinds). Worst-case scenario indicates $39 should be bottom and $41 in 12 months, assuming worst-case 2025/2026 EBITDA declines (highly unlikely, in our view). For investors not prepared to stomach more volatility and potential short-term pressure, we believe Andlauer should hold-up best."